{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,25]],"date-time":"2026-07-25T11:43:28Z","timestamp":1784979808931,"version":"3.55.0"},"reference-count":61,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2024,4,6]],"date-time":"2024-04-06T00:00:00Z","timestamp":1712361600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2024,4,6]],"date-time":"2024-04-06T00:00:00Z","timestamp":1712361600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"National Institute of Arthritis and Musculoskeletal and Skin Diseases of the National Institutes of Health","award":["K23AR077073"],"award-info":[{"award-number":["K23AR077073"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Prurigo nodularis (PN) is a chronic inflammatory skin disease that is associated with variability in peripheral blood eosinophil levels and response to T-helper 2 targeted therapies (Th2). Our objective was to determine whether circulating immune profiles with respect to type 2 inflammation differ by race and peripheral blood eosinophil count. Plasma from 56 PN patients and 13 matched healthy controls was assayed for 54 inflammatory biomarkers. We compared biomarker levels between PN and HCs, among PN patients based on absolute eosinophil count, and across racial groups in PN. Eleven biomarkers were elevated in PN versus HCs including interleukin (IL)-12\/IL-23p40, tumor necrosis factor-alpha (TNF-\u03b1), Thymic stromal lymphopoietin (TSLP), and macrophage-derived chemokine (MDC\/CCL22). Additionally, PN patients with AEC\u2009&gt;\u20090.3\u00a0K cells\/\u03bcL had higher Th2 markers (eotaxin, eotaxin-3, TSLP, MCP-4\/CCL13), and African American PN patients had lower eosinophils, eotaxin, and eotaxin-3 versus Caucasian and Asian PN patients (p\u2009&lt;\u20090.05 for all). Dupilumab responders had higher AEC (p\u2009&lt;\u20090.01), were more likely to be Caucasian (p\u2009=\u20090.02) or Asian (p\u2009=\u20090.05) compared to African Americans, and more often had a history of atopy (p\u2009=\u20090.08). This study suggests that blood AEC\u2009&gt;\u20090.3\u00a0K and Asian and Caucasian races are associated with Th2 skewed circulating immune profiles and response to Th2 targeted therapies.<\/jats:p>","DOI":"10.1038\/s41598-024-58013-x","type":"journal-article","created":{"date-parts":[[2024,4,6]],"date-time":"2024-04-06T10:01:34Z","timestamp":1712397694000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":15,"title":["Comprehensive plasma cytokine and chemokine profiling in prurigo nodularis reveals endotypes in Type 2 inflammation"],"prefix":"10.1038","volume":"14","author":[{"given":"Hannah L.","family":"Cornman","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jaya","family":"Manjunath","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sriya V.","family":"Reddy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jackson","family":"Adams","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ahmad","family":"Rajeh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christeen","family":"Samuel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aaron","family":"Bao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ryan","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emily Z.","family":"Ma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jason","family":"Shumsky","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas W.","family":"Pritchard","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brenda Umenita","family":"Imo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexander L.","family":"Kollhoff","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kevin K.","family":"Lee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Weiying","family":"Lu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Selina","family":"Yossef","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Madan M.","family":"Kwatra","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shawn G.","family":"Kwatra","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,4,6]]},"reference":[{"key":"58013_CR1","doi-asserted-by":"publisher","first-page":"336","DOI":"10.1001\/jamadermatol.2021.5307","volume":"158","author":"SG Kwatra","year":"2022","unstructured":"Kwatra, S. G. Prurigo nodularis. JAMA Dermatol. 158, 336 (2022).","journal-title":"JAMA Dermatol."},{"key":"58013_CR2","doi-asserted-by":"publisher","first-page":"573","DOI":"10.1016\/j.jaad.2021.05.036","volume":"86","author":"KA Whang","year":"2022","unstructured":"Whang, K. A. et al. Health-related quality of life and economic burden of prurigo nodularis. J. Am. Acad. Dermatol. 86, 573\u2013580 (2022).","journal-title":"J. Am. Acad. Dermatol."},{"key":"58013_CR3","doi-asserted-by":"publisher","first-page":"2530","DOI":"10.1016\/j.jid.2021.02.756","volume":"141","author":"S Wongvibulsin","year":"2021","unstructured":"Wongvibulsin, S. et al. A nationwide study of prurigo nodularis: Disease burden and healthcare utilization in the United States. J. Invest. Dermatol. 141, 2530\u20132533 (2021).","journal-title":"J. Invest. Dermatol."},{"key":"58013_CR4","doi-asserted-by":"publisher","first-page":"2208","DOI":"10.1016\/j.jid.2021.02.749","volume":"141","author":"M Belzberg","year":"2021","unstructured":"Belzberg, M. et al. Prurigo nodularis is characterized by systemic and cutaneous T helper 22 immune polarization. J. Invest. Dermatol. 141, 2208\u20132218 (2021).","journal-title":"J. Invest. Dermatol."},{"key":"58013_CR5","doi-asserted-by":"publisher","first-page":"1101","DOI":"10.1016\/j.jaad.2023.01.042","volume":"88","author":"V Parthasarathy","year":"2023","unstructured":"Parthasarathy, V. et al. The blood proteomic signature of prurigo nodularis reveals distinct inflammatory and neuropathic endotypes: A cluster analysis. J. Am. Acad. Dermatol. 88, 1101\u20131109 (2023).","journal-title":"J. Am. Acad. Dermatol."},{"key":"58013_CR6","doi-asserted-by":"publisher","first-page":"1011142","DOI":"10.3389\/fmed.2022.1011142","volume":"9","author":"V Parthasarathy","year":"2022","unstructured":"Parthasarathy, V. et al. Circulating plasma IL-13 and periostin are dysregulated type 2 inflammatory biomarkers in prurigo nodularis: A cluster analysis. Front. Med. 9, 1011142 (2022).","journal-title":"Front. Med."},{"key":"58013_CR7","doi-asserted-by":"publisher","first-page":"00861","DOI":"10.2340\/actadv.v103.4804","volume":"103","author":"T Ju","year":"2023","unstructured":"Ju, T. et al. Serum interleukin-13 and caspase 8 are elevated in prurigo nodularis. Acta Derm. Venereol. 103, 00861 (2023).","journal-title":"Acta Derm. Venereol."},{"key":"58013_CR8","doi-asserted-by":"publisher","first-page":"977","DOI":"10.1001\/jamadermatol.2023.2609","volume":"159","author":"J Deng","year":"2023","unstructured":"Deng, J. et al. Modulation of neuroimmune and epithelial dysregulation in patients with moderate to severe prurigo nodularis treated with nemolizumab. JAMA Dermatol. 159, 977\u2013985 (2023).","journal-title":"JAMA Dermatol."},{"issue":"23","key":"58013_CR9","doi-asserted-by":"publisher","first-page":"01265","DOI":"10.1016\/j.jaad.2023.06.045","volume":"S0190\u20139622","author":"MZ Joel","year":"2023","unstructured":"Joel, M. Z., Hydol-Smith, J., Kambala, A., Cornman, H. L. & Kwatra, S. G. Prevalence and comorbidity burden of prurigo nodularis in United States adults enrolled in the all of us research program. J. Am. Acad. Dermatol. S0190\u20139622(23), 01265\u201301273. https:\/\/doi.org\/10.1016\/j.jaad.2023.06.045 (2023).","journal-title":"J. Am. Acad. Dermatol."},{"key":"58013_CR10","doi-asserted-by":"publisher","first-page":"1198","DOI":"10.1016\/j.jaad.2019.03.083","volume":"81","author":"VA Larson","year":"2019","unstructured":"Larson, V. A. et al. Association between prurigo nodularis and malignancy in middle-aged adults. J. Am. Acad. Dermatol. 81, 1198\u20131201 (2019).","journal-title":"J. Am. Acad. Dermatol."},{"key":"58013_CR11","doi-asserted-by":"publisher","first-page":"714","DOI":"10.1016\/j.jaad.2018.04.047","volume":"79","author":"E Boozalis","year":"2018","unstructured":"Boozalis, E. et al. Ethnic differences and comorbidities of 909 prurigo nodularis patients. J. Am. Acad. Dermatol. 79, 714\u2013719 (2018).","journal-title":"J. Am. Acad. Dermatol."},{"key":"58013_CR12","doi-asserted-by":"publisher","first-page":"1567","DOI":"10.1016\/j.jaad.2020.04.182","volume":"83","author":"KA Williams","year":"2020","unstructured":"Williams, K. A., Huang, A. H., Belzberg, M. & Kwatra, S. G. Prurigo nodularis: Pathogenesis and management. J. Am. Acad. Dermatol. 83, 1567\u20131575 (2020).","journal-title":"J. Am. Acad. Dermatol."},{"key":"58013_CR13","doi-asserted-by":"publisher","DOI":"10.1101\/2023.01.29.526050","author":"JR Patel","year":"2023","unstructured":"Patel, J. R. et al. Single-cell RNA sequencing reveals dysregulated fibroblast subclusters in prurigo nodularis. BioRxiv https:\/\/doi.org\/10.1101\/2023.01.29.526050 (2023).","journal-title":"BioRxiv"},{"key":"58013_CR14","doi-asserted-by":"publisher","first-page":"903","DOI":"10.1111\/bjd.20957","volume":"186","author":"S Wongvibulsin","year":"2022","unstructured":"Wongvibulsin, S. et al. Latent class analysis identification of prurigo nodularis comorbidity phenotypes. Br. J. Dermatol. 186, 903\u2013905 (2022).","journal-title":"Br. J. Dermatol."},{"key":"58013_CR15","doi-asserted-by":"publisher","DOI":"10.1016\/j.jid.2023.04.033","author":"C Vasavda","year":"2023","unstructured":"Vasavda, C. et al. A polygenic risk score for predicting racial and genetic susceptibility to prurigo nodularis. J. Invest. Dermatol. https:\/\/doi.org\/10.1016\/j.jid.2023.04.033 (2023).","journal-title":"J. Invest. Dermatol."},{"key":"58013_CR16","doi-asserted-by":"publisher","first-page":"487","DOI":"10.1016\/j.jaad.2021.09.028","volume":"86","author":"N Sutaria","year":"2022","unstructured":"Sutaria, N. et al. Racial disparities in mortality among patients with prurigo nodularis: A multi-center cohort study. J. Am. Acad. Dermatol. 86, 487\u2013490 (2022).","journal-title":"J. Am. Acad. Dermatol."},{"key":"58013_CR17","first-page":"30","volume":"113","author":"M McColl","year":"2021","unstructured":"McColl, M. et al. Pruritus in black skin: Unique molecular characteristics and clinical features. J. Natl. Med. Assoc. 113, 30\u201338 (2021).","journal-title":"J. Natl. Med. Assoc."},{"key":"58013_CR18","doi-asserted-by":"publisher","first-page":"1300","DOI":"10.1016\/j.jid.2021.10.011","volume":"142","author":"N Sutaria","year":"2022","unstructured":"Sutaria, N. et al. Cluster analysis of circulating plasma biomarkers in prurigo nodularis reveals a distinct systemic inflammatory signature in African Americans. J. Invest. Dermatol. 142, 1300\u20131308 (2022).","journal-title":"J. Invest. Dermatol."},{"key":"58013_CR19","doi-asserted-by":"publisher","first-page":"1180","DOI":"10.1038\/s41591-023-02320-9","volume":"29","author":"G Yosipovitch","year":"2023","unstructured":"Yosipovitch, G. et al. Dupilumab in patients with prurigo nodularis: Two randomized, double-blind, placebo-controlled phase 3 trials. Nat. Med. 29, 1180\u20131190 (2023).","journal-title":"Nat. Med."},{"key":"58013_CR20","doi-asserted-by":"publisher","first-page":"162056","DOI":"10.1093\/bjd\/ljad162.056","volume":"188","author":"S St\u00e4nder","year":"2023","unstructured":"St\u00e4nder, S. et al. 436 Nemolizumab monotherapy was associated with significant improvements in prurigo activity score in adult patients with moderate-to-severe prurigo nodularis: Results from a phase 3 trial (OLYMPIA 2). Br. J. Dermatol. 188, 162056 (2023).","journal-title":"Br. J. Dermatol."},{"key":"58013_CR21","doi-asserted-by":"publisher","first-page":"573","DOI":"10.1111\/jdv.17870","volume":"36","author":"S St\u00e4nder","year":"2022","unstructured":"St\u00e4nder, S. et al. Worst itch numerical rating scale for prurigo nodularis: A psychometric evaluation. J. Eur. Acad. Dermatol. Venereol. 36, 573\u2013581 (2022).","journal-title":"J. Eur. Acad. Dermatol. Venereol."},{"key":"58013_CR22","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1111\/cea.13491","volume":"50","author":"H Harb","year":"2020","unstructured":"Harb, H. & Chatila, T. A. Mechanisms of dupilumab. Clin. Exp. Allergy 50, 5\u201314 (2020).","journal-title":"Clin. Exp. Allergy"},{"key":"58013_CR23","doi-asserted-by":"publisher","first-page":"204062232211125","DOI":"10.1177\/20406223221112561","volume":"13","author":"S Chaowattanapanit","year":"2022","unstructured":"Chaowattanapanit, S. et al. Increased IL-31 expression in serum and tissue protein in prurigo nodularis. Ther. Adv. Chronic Dis. 13, 20406223221112560 (2022).","journal-title":"Ther. Adv. Chronic Dis."},{"key":"58013_CR24","doi-asserted-by":"publisher","first-page":"24","DOI":"10.1016\/j.ajp.2015.07.010","volume":"17","author":"D Konda","year":"2015","unstructured":"Konda, D. et al. Serotonin and interleukin-6: Association with pruritus severity, sleep quality and depression severity in Prurigo Nodularis. Asian J. Psychiatr. 17, 24\u201328 (2015).","journal-title":"Asian J. Psychiatr."},{"key":"58013_CR25","doi-asserted-by":"publisher","first-page":"94","DOI":"10.1002\/cia2.12062","volume":"2","author":"T Ishikawa","year":"2019","unstructured":"Ishikawa, T., Hashimoto, T., Munetsugu, T., Yokozeki, H. & Satoh, T. Increased \u03b2-endorphin and autotaxin in patients with prurigo. J. Cutan. Immunol. Allergy 2, 94\u2013101 (2019).","journal-title":"J. Cutan. Immunol. Allergy"},{"key":"58013_CR26","doi-asserted-by":"publisher","DOI":"10.1007\/978-94-007-7696-8_27","author":"I Bhavsar","year":"2015","unstructured":"Bhavsar, I., Miller, C. S. & Al-Sabbagh, M. Macrophage inflammatory protein-1 alpha (MIP-1 alpha)\/CCL3: As a biomarker. Gen. Methods Biomark. Res. Appl. https:\/\/doi.org\/10.1007\/978-94-007-7696-8_27 (2015).","journal-title":"Gen. Methods Biomark. Res. Appl."},{"key":"58013_CR27","doi-asserted-by":"publisher","first-page":"5187","DOI":"10.1158\/0008-5472.CAN-15-1498","volume":"75","author":"K Pilipow","year":"2015","unstructured":"Pilipow, K. et al. IL-15 and T cell stemness in T cell-based cancer immunotherapy. Cancer Res. 75, 5187\u20135193 (2015).","journal-title":"Cancer Res."},{"key":"58013_CR28","doi-asserted-by":"publisher","first-page":"1595","DOI":"10.1084\/jem.185.9.1595","volume":"185","author":"R Godiska","year":"1997","unstructured":"Godiska, R. et al. Human macrophage\u2013derived chemokine (MDC), a novel chemoattractant for monocytes, monocyte-derived dendritic cells, and natural killer cells. J. Exp. Med. 185, 1595\u20131604 (1997).","journal-title":"J. Exp. Med."},{"key":"58013_CR29","doi-asserted-by":"publisher","first-page":"270","DOI":"10.1046\/j.1365-2249.2002.01727.x","volume":"127","author":"T Kakinuma","year":"2002","unstructured":"Kakinuma, T. et al. Serum macrophage-derived chemokine (MDC) levels are closely related with the disease activity of atopic dermatitis. Clin. Exp. Immunol. 127, 270\u2013273 (2002).","journal-title":"Clin. Exp. Immunol."},{"key":"58013_CR30","doi-asserted-by":"publisher","first-page":"400","DOI":"10.1189\/jlb.68.3.400","volume":"68","author":"A Mantovani","year":"2000","unstructured":"Mantovani, A., Gray, P. A., Van Damme, J. & Sozzani, S. Macrophage-derived chemokine (MDC). J. Leukoc. Biol. 68, 400\u2013404 (2000).","journal-title":"J. Leukoc. Biol."},{"key":"58013_CR31","doi-asserted-by":"publisher","first-page":"737","DOI":"10.1016\/j.jaci.2022.11.009","volume":"151","author":"T Hashimoto","year":"2023","unstructured":"Hashimoto, T., Yokozeki, H., Karasuyama, H. & Satoh, T. IL-31-generating network in atopic dermatitis comprising macrophages, basophils, thymic stromal lymphopoietin, and periostin. J. Allergy Clin. Immunol. 151, 737-746.e6 (2023).","journal-title":"J. Allergy Clin. Immunol."},{"key":"58013_CR32","doi-asserted-by":"publisher","DOI":"10.1016\/j.celrep.2020.03.036","volume":"31","author":"SK Mishra","year":"2020","unstructured":"Mishra, S. K. et al. Periostin activation of integrin receptors on sensory neurons induces allergic itch. Cell Rep. 31, 107472 (2020).","journal-title":"Cell Rep."},{"key":"58013_CR33","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1615\/CritRevImmunol.v32.i1.30","volume":"32","author":"SS Iyer","year":"2012","unstructured":"Iyer, S. S. & Cheng, G. Role of interleukin 10 transcriptional regulation in inflammation and autoimmune disease. Crit. Rev. Immunol. 32, 23\u201363 (2012).","journal-title":"Crit. Rev. Immunol."},{"key":"58013_CR34","doi-asserted-by":"publisher","first-page":"1956","DOI":"10.4049\/jimmunol.154.4.1956","volume":"154","author":"JD Ohmen","year":"1995","unstructured":"Ohmen, J. D. et al. Overexpression of IL-10 in atopic dermatitis: Contrasting cytokine patterns with delayed-type hypersensitivity reactions. J. Immunol. 154, 1956\u20131963 (1995).","journal-title":"J. Immunol."},{"key":"58013_CR35","doi-asserted-by":"publisher","first-page":"285","DOI":"10.3389\/fcvm.2021.737285","volume":"8","author":"F Contreras-Brice\u00f1o","year":"2021","unstructured":"Contreras-Brice\u00f1o, F. et al. Circulating vascular cell adhesion molecule-1 (sVCAM-1) is associated with left atrial remodeling in long-distance runners. Front. Cardiovasc. Med. 8, 285 (2021).","journal-title":"Front. Cardiovasc. Med."},{"key":"58013_CR36","first-page":"91","volume":"15","author":"AM Witkowska","year":"2004","unstructured":"Witkowska, A. M. & Borawska, M. H. Soluble intercellular adhesion molecule-1 (sICAM-1): An overview. Eur. Cytokine Netw. 15, 91\u201398 (2004).","journal-title":"Eur. Cytokine Netw."},{"key":"58013_CR37","doi-asserted-by":"publisher","first-page":"335","DOI":"10.1615\/CritRevImmunol.v32.i4.40","volume":"32","author":"KK Eklund","year":"2012","unstructured":"Eklund, K. K., Niemi, K. & Kovanen, P. T. Immune functions of serum amyloid A. Crit. Rev. Immunol. 32, 335\u2013348 (2012).","journal-title":"Crit. Rev. Immunol."},{"key":"58013_CR38","doi-asserted-by":"publisher","first-page":"166170","DOI":"10.1016\/j.bbadis.2021.166170","volume":"1867","author":"MF Troncoso","year":"2021","unstructured":"Troncoso, M. F. et al. VCAM-1 as a predictor biomarker in cardiovascular disease. Biochim. Biophys. Acta Mol. Basis Dis. 1867, 166170 (2021).","journal-title":"Biochim. Biophys. Acta Mol. Basis Dis."},{"key":"58013_CR39","doi-asserted-by":"publisher","DOI":"10.1373\/clinchem.2011.168559","author":"MD Gross","year":"2012","unstructured":"Gross, M. D. et al. Circulating soluble ICAM-1 and subclinical atherosclerosis: The coronary artery risk development in young adults (CARDIA) study. Clin. Chem. https:\/\/doi.org\/10.1373\/clinchem.2011.168559 (2012).","journal-title":"Clin. Chem."},{"key":"58013_CR40","doi-asserted-by":"publisher","unstructured":"Chapter 6: Eosinophil trafficking. in Eosinophils in Health and Disease (eds. Lee, J. J. & Rosenberg, H. F.) 121\u2013166 (Academic Press, 2013). https:\/\/doi.org\/10.1016\/B978-0-12-394385-9.00006-7.","DOI":"10.1016\/B978-0-12-394385-9.00006-7"},{"key":"58013_CR41","doi-asserted-by":"publisher","DOI":"10.1016\/j.intimp.2021.107598","volume":"101","author":"S Singh","year":"2021","unstructured":"Singh, S., Anshita, D. & Ravichandiran, V. MCP-1: Function, regulation, and involvement in disease. Int. Immunopharmacol. 101, 107598 (2021).","journal-title":"Int. Immunopharmacol."},{"key":"58013_CR42","doi-asserted-by":"publisher","first-page":"2379","DOI":"10.1084\/jem.183.5.2379","volume":"183","author":"M Uguccioni","year":"1996","unstructured":"Uguccioni, M. et al. Monocyte chemotactic protein 4 (MCP-4), a novel structural and functional analogue of MCP-3 and eotaxin. J. Exp. Med. 183, 2379\u20132384 (1996).","journal-title":"J. Exp. Med."},{"key":"58013_CR43","doi-asserted-by":"publisher","first-page":"514","DOI":"10.3389\/fphys.2019.01514","volume":"10","author":"C Pelaia","year":"2019","unstructured":"Pelaia, C. et al. Interleukin-5 in the pathophysiology of severe asthma. Front. Physiol. 10, 514 (2019).","journal-title":"Front. Physiol."},{"key":"58013_CR44","doi-asserted-by":"publisher","first-page":"S250","DOI":"10.1016\/j.jaci.2008.12.964","volume":"123","author":"Y Hiraguchi","year":"2009","unstructured":"Hiraguchi, Y., Hosoki, K., Nagao, M., Tokuda, R. & Fujisawa, T. Thymic stromal lymphopoietin directly activates eosinophils. J. Allergy Clin. Immunol. 123, S250 (2009).","journal-title":"J. Allergy Clin. Immunol."},{"key":"58013_CR45","doi-asserted-by":"publisher","first-page":"250","DOI":"10.1038\/icb.2009.115","volume":"88","author":"LA Spencer","year":"2010","unstructured":"Spencer, L. A. & Weller, P. F. Eosinophils and Th2 immunity: Contemporary insights. Immunol. Cell Biol. 88, 250\u2013256 (2010).","journal-title":"Immunol. Cell Biol."},{"key":"58013_CR46","doi-asserted-by":"publisher","first-page":"1305","DOI":"10.3904\/kjim.2021.180","volume":"36","author":"A Li","year":"2021","unstructured":"Li, A. et al. Eosinophilic endotype of chronic obstructive pulmonary disease: Similarities and differences from asthma. Korean J. Intern. Med. 36, 1305\u20131319 (2021).","journal-title":"Korean J. Intern. Med."},{"key":"58013_CR47","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.jaci.2018.10.032","volume":"143","author":"T Czarnowicki","year":"2019","unstructured":"Czarnowicki, T., He, H., Krueger, J. G. & Guttman-Yassky, E. Atopic dermatitis endotypes and implications for targeted therapeutics. J. Allergy Clin. Immunol. 143, 1\u201311 (2019).","journal-title":"J. Allergy Clin. Immunol."},{"key":"58013_CR48","doi-asserted-by":"publisher","first-page":"2513","DOI":"10.1016\/j.jaip.2021.01.034","volume":"9","author":"YS Roh","year":"2021","unstructured":"Roh, Y. S. et al. Circulating blood eosinophils as a biomarker for variable clinical presentation and therapeutic response in patients with chronic pruritus of unknown origin. J. Allergy Clin. Immunol. Pract. 9, 2513\u20132516 (2021).","journal-title":"J. Allergy Clin. Immunol. Pract."},{"key":"58013_CR49","doi-asserted-by":"publisher","first-page":"559","DOI":"10.1016\/j.iac.2016.03.006","volume":"36","author":"F Aleman","year":"2016","unstructured":"Aleman, F., Lim, H. F. & Nair, P. Eosinophilic endotype of asthma. Immunol. Allergy Clin. N. Am. 36, 559\u2013568 (2016).","journal-title":"Immunol. Allergy Clin. N. Am."},{"key":"58013_CR50","doi-asserted-by":"publisher","first-page":"1093","DOI":"10.3390\/jpm12071093","volume":"12","author":"K Porpodis","year":"2022","unstructured":"Porpodis, K. et al. Eosinophilic asthma, phenotypes-endotypes and current biomarkers of choice. J. Pers. Med. 12, 1093 (2022).","journal-title":"J. Pers. Med."},{"key":"58013_CR51","doi-asserted-by":"publisher","first-page":"990","DOI":"10.1111\/j.1365-2133.2011.10498.x","volume":"165","author":"S Fukushi","year":"2011","unstructured":"Fukushi, S., Yamasaki, K. & Aiba, S. Nuclear localization of activated STAT6 and STAT3 in epidermis of prurigo nodularis. Br. J. Dermatol. 165, 990\u2013996 (2011).","journal-title":"Br. J. Dermatol."},{"key":"58013_CR52","doi-asserted-by":"publisher","first-page":"1840","DOI":"10.1016\/j.jaip.2020.02.022","volume":"8","author":"T Nomura","year":"2020","unstructured":"Nomura, T., Wu, J., Kabashima, K. & Guttman-Yassky, E. Endophenotypic variations of atopic dermatitis by age, race, and ethnicity. J. Allergy Clin. Immunol. Pract. 8, 1840\u20131852 (2020).","journal-title":"J. Allergy Clin. Immunol. Pract."},{"key":"58013_CR53","doi-asserted-by":"publisher","DOI":"10.1136\/openhrt-2016-000477","volume":"3","author":"AD Shah","year":"2016","unstructured":"Shah, A. D., Denaxas, S., Nicholas, O., Hingorani, A. D. & Hemingway, H. Low eosinophil and low lymphocyte counts and the incidence of 12 cardiovascular diseases: A CALIBER cohort study. Open Heart 3, e000477 (2016).","journal-title":"Open Heart"},{"key":"58013_CR54","doi-asserted-by":"publisher","first-page":"1559","DOI":"10.1016\/j.jaad.2020.04.183","volume":"83","author":"AH Huang","year":"2020","unstructured":"Huang, A. H., Williams, K. A. & Kwatra, S. G. Prurigo nodularis: Epidemiology and clinical features. J. Am. Acad. Dermatol. 83, 1559\u20131565 (2020).","journal-title":"J. Am. Acad. Dermatol."},{"key":"58013_CR55","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1056\/NEJMoa1908316","volume":"382","author":"S St\u00e4nder","year":"2020","unstructured":"St\u00e4nder, S. et al. Trial of nemolizumab in moderate-to-severe prurigo nodularis. N. Engl. J. Med. 382, 1\u201310 (2020).","journal-title":"N. Engl. J. Med."},{"key":"58013_CR56","doi-asserted-by":"publisher","first-page":"00401","DOI":"10.2340\/00015555-3701","volume":"101","author":"C Zeidler","year":"2021","unstructured":"Zeidler, C., Pereira, M. P., Augustin, M., Spellman, M. & St\u00e4nder, S. Investigator\u2019s global assessment of chronic prurigo: A new instrument for use in clinical trials. Acta Derm. Venereol. 101, 00401 (2021).","journal-title":"Acta Derm. Venereol."},{"key":"58013_CR57","doi-asserted-by":"publisher","first-page":"1882","DOI":"10.2174\/1389450119666180212120012","volume":"19","author":"K Kostikas","year":"2018","unstructured":"Kostikas, K., Brindicci, C. & Patalano, F. Blood eosinophils as biomarkers to drive treatment choices in asthma and COPD. Curr. Drug Targets 19, 1882\u20131896 (2018).","journal-title":"Curr. Drug Targets"},{"key":"58013_CR58","doi-asserted-by":"publisher","first-page":"747","DOI":"10.1016\/j.jaad.2020.07.025","volume":"84","author":"S Elmariah","year":"2021","unstructured":"Elmariah, S. et al. Practical approaches for diagnosis and management of prurigo nodularis: United States expert panel consensus. J. Am. Acad. Dermatol. 84, 747\u2013760 (2021).","journal-title":"J. Am. Acad. Dermatol."},{"key":"58013_CR59","doi-asserted-by":"publisher","first-page":"322","DOI":"10.1186\/s12967-023-04179-3","volume":"21","author":"L Giloteaux","year":"2023","unstructured":"Giloteaux, L. et al. Proteomics and cytokine analyses distinguish myalgic encephalomyelitis\/chronic fatigue syndrome cases from controls. J. Transl. Med. 21, 322 (2023).","journal-title":"J. Transl. Med."},{"key":"58013_CR60","doi-asserted-by":"publisher","first-page":"698","DOI":"10.3390\/jof7090698","volume":"7","author":"CD Lauruschkat","year":"2021","unstructured":"Lauruschkat, C. D. et al. Chronic occupational mold exposure drives expansion of aspergillus-reactive type 1 and type 2 T-helper cell responses. J. Fungi 7, 698 (2021).","journal-title":"J. Fungi"},{"key":"58013_CR61","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.2022928118","volume":"118","author":"CJ LopezAngel","year":"2021","unstructured":"LopezAngel, C. J. et al. Signatures of immune dysfunction in HIV and HCV infection share features with chronic inflammation in aging and persist after viral reduction or elimination. Proc. Natl. Acad. Sci. USA 118, e2022928118 (2021).","journal-title":"Proc. Natl. Acad. Sci. USA"}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-024-58013-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-024-58013-x","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-024-58013-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,4,6]],"date-time":"2024-04-06T10:04:52Z","timestamp":1712397892000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-024-58013-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,4,6]]},"references-count":61,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2024,12]]}},"alternative-id":["58013"],"URL":"https:\/\/doi.org\/10.1038\/s41598-024-58013-x","relation":{},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,4,6]]},"assertion":[{"value":"27 November 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"25 March 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 April 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Dr. Kwatra is an advisory board member\/consultant for Abbvie, Aslan Pharmaceuticals, Arcutis Biotherapeutics, Castle Biosciences, Celldex Therapeutics, Galderma, Genzada Pharmaceuticals, Incyte Corporation, Johnson & Johnson, Leo Pharma, Novartis Pharmaceuticals Corporation, Pfizer, Regeneron Pharmaceuticals, and Sanofi and has served as an investigator for Galderma, Incyte, Pfizer, and Sanofi. All other authors report no conflicts of interest.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"8098"}}